Format

Send to

Choose Destination
Curr Opin Pharmacol. 2015 Aug;23:45-51. doi: 10.1016/j.coph.2015.05.008. Epub 2015 Jun 4.

CSF-1/CSF-1R targeting agents in clinical development for cancer therapy.

Author information

1
Roche Pharmaceutical Research and Early Development, Roche Innovation Center Penzberg, Nonnenwald 2, 82377 Penzberg, Germany. Electronic address: carola.ries@roche.com.
2
Roche Pharmaceutical Research and Early Development, Roche Innovation Center Penzberg, Nonnenwald 2, 82377 Penzberg, Germany.

Abstract

Macrophage infiltration has been identified as an independent poor prognostic factor for several cancer entities. In mouse tumor models macrophages orchestrate various tumor-promoting processes. This observation sparked an interest to therapeutically target these plastic innate immune cells. To date, blockade of colony stimulating factor-1 or its receptor represents the only truly selective approach to manipulate macrophages in cancer patients. Here, we discuss the currently available information on efficacy and safety of various CSF-1/CSF-1R inhibitors in cancer patients and highlight potential combination partners emerging from preclinical studies while considering the differences between mouse and human macrophage biology.

PMID:
26051995
DOI:
10.1016/j.coph.2015.05.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center